Sight Sciences Secures Order on Post-Trial Motions
PALO ALTO – April 23, 2026 – Cooley represented Sight Sciences (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, in defeating post-trial motions to reverse its jury trial patent infringement verdict.
Cooley secured a jury trial patent infringement victory on behalf of Sight Sciences on April 26, 2024. The jury found that Alcon’s and Ivantis’ sale of the infringing Hydrus Microstent caused Sight Sciences to lose sales of its OMNI Surgical System device and awarded lost profits damages and royalty damages totaling $34 million.
On April 20, 2026, the US District Court for the District of Delaware preserved the jury’s verdict of willful infringement, denied Alcon’s request for judgment as a matter of law and a new trial, and awarded total damages of $55.4 million, plus an ongoing royalty of 10% of Hydrus revenue through the date of expiration of Sight Sciences’ last asserted patent. The value of the court’s final judgment is expected to increase significantly with the payment of ongoing royalties over the next two and a half years.
The patents at issue are US Patent Nos. 8,287,482, 9,370,443 and 11,389,328.
The Cooley litigation team was led by intellectual property litigation partner Orion Armon with partners Mika Reiner Mayer, Joanna Liebes Hubberts and Eamonn Gardner; senior counsel Michelle Rhyu ; and associates Joseph Van Tassel, Dustin Knight, Lauren Strosnick, Juan Pablo Gonzalez and Angela Madrigal.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.